Gyre Therapeutics Inc. (GYRE)vsRegeneron Pharmaceuticals Inc (REGN)
GYRE
Gyre Therapeutics Inc.
$7.49
+1.90%
HEALTHCARE · Cap: $779.35M
REGN
Regeneron Pharmaceuticals Inc
$752.25
-4.54%
HEALTHCARE · Cap: $82.55B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 14046% more annual revenue ($15.53B vs $109.82M). REGN leads profitability with a 27.9% profit margin vs -19.3%. REGN earns a higher WallStSmart Score of 66/100 (B-).
GYRE
Avoid23
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GYRE.
Margin of Safety
+43.2%
Fair Value
$1400.68
Current Price
$752.25
$648.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 166.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -13.3% — below average capital efficiency
Revenue declined 2.1%
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : GYRE
The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : GYRE
The primary concerns for GYRE are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
GYRE profiles as a turnaround stock while REGN is a growth play — different risk/reward profiles.
GYRE carries more volatility with a beta of 4.83 — expect wider price swings.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (66/100 vs 23/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary platform that harmoniously combines gene therapy with precision medicine, Gyre is focused on delivering innovative solutions to address significant unmet medical needs. With a robust pipeline and a strong commitment to scientific excellence, the company is well-positioned for sustained growth and impact in the biopharmaceutical sector. Its strategic collaborations and ongoing research and development efforts underscore Gyre's potential to revolutionize treatment paradigms and improve patient outcomes in challenging health conditions.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?